Anavex Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s

 Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement

Submission based on favorable ANAVEX®2-73-AD-004 trial results in patients with early Alzheimer’s disease

Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer's disease patients, demonstrating a favorable safety profile with no associated neuroimaging adverse events

https://www.globenewswire.com/news-release/2024/12/23/3001118/29248/en/Blarcamesine-Receives-EMA-Filing-Acceptance-for-Treatment-of-Alzheimer-s-Disease.html